Study uncovers a promising therapeutic target for retinal dystrophies

NewsGuard 100/100 Score

A team of LSU Health New Orleans researchers reports for the first time that deleting one of the inhibitors of the RPE65 gene in a mouse model that carries a human disease mutation prevents degeneration of cone photoreceptors that are used for daytime high-resolution color vision. Their findings are published in PNAS available here.

More than 100 DNA variants in the RPE65 gene are reported as pathogenic mutations causing retinal degenerative diseases. They include a group of inherited childhood blinding diseases called Leber congenital amaurosis (LCA). While a new gene therapy may improve vision for some with RPE65 gene mutations, there is currently no effective therapy that arrests progressive retinal degeneration in LCA.

Previously, the researchers identified three inhibitors of RPE65. The one involved in the current study is called fatty acid transport protein 4 (FATP4). They found that the survival of cone photoreceptors is increased nearly 10-fold in the mouse model of LCA lacking FATP4 in the retina. They also discovered that partial reduction of FATP4 in the retina can improve the survival and visual function of cone photoreceptors. These findings establish FATP4 as a promising therapeutic target to preserve daytime color vision in patients.

The role of FATP4 in disease progression of retinal dystrophies associated with RPE65 mutations was completely unknown. This study is the first to uncover that FATP4 plays a pivotal role in photoreceptor survival and function in retinal dystrophies."

Nicolas Bazan, MD, PhD, Boyd Professor, Ernest and Yvette C. Villere Endowed Chair for Retinal Degenerative Diseases and Director of the Neuroscience Center of Excellence at LSU Health New Orleans School of Medicine

According to the National Institutes of Health, Leber congenital amaurosis primarily affects the retina, the specialized tissue at the back of the eye that detects light and color. Beginning in infancy, people with LCA typically have severe visual impairment. The National Library of Medicine says Leber congenital amaurosis occurs in 2 to 3 per 100,000 newborns. It is one of the most common causes of blindness in children.

Our findings have allowed us to envision a strategy to mitigate the cone photoreceptor degeneration and vision loss in patients with RPE65 mutations as well as in other mutations."

Minghao Jin, Ph.D., Professor of Neuroscience and Ophthalmology at LSU Health New Orleans School of Medicine

Source:
Journal reference:

Li, S., et al. (2020) Inverse correlation between fatty acid transport protein 4 and vision in Leber congenital amaurosis associated with RPE65 mutation. PNAS. doi.org/10.1073/pnas.2012623117.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals how DNA gyrase resolves DNA entanglements